Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

StemRIM

company

About

StemRIM is a bio company that aims to develop "regeneration-inducing medicines".

  • Osaka,Osaka,Japan
  • 51 - 100

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
¥745.02M
Industries
Biotechnology,Medical,Product Research
Founded date
Oct 30, 2006
Number Of Employee
51 - 100
Operating Status
Active
Stock Symbol
tyo:4599
Legal Name
Stem Rim Co., Ltd.
Also Known As
株式会社ステムリム

Stem Rim is a biotechnology company aiming to develop “regenerative medicine”.We are developing drugs based on a new mechanism of action that mobilizes stem cells present in the living body to the injured or diseased tissue without removing them out of the body and induces functional tissue regeneration.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
¥3.44B
StemRIM has raised a total of ¥3.44B in funding over 2 rounds. Their latest funding was raised on Aug 9, 2019 from a IPO round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 9, 2019 IPO Detail
Dec 28, 2018 Series Unknown ¥745.02M 6 Detail
Dec 7, 2018 Series Unknown ¥699.93M 1 DCI Partners Detail
Dec 15, 2017 Series Unknown ¥199.98M 1 Mitsubishi UFJ Capital Detail
Nov 17, 2017 Series Unknown ¥1B 10 Detail

Investors

Number of Lead Investors
Number of Investors
3
13
StemRIM is funded by 13 investors. DCI Partners and Mitsubishi UFJ Capital are the most recent investors.
Investor Name Lead Investor Funding Round
DCI Partners Yes Series Unknown
Mitsubishi UFJ Capital Yes Series Unknown
Shionogi Yes Corporate Round
M3i Series Unknown
KSP Series Unknown
Kyogin Lease & Capital Series Unknown
M3 Series Unknown
Miyako Capital Series Unknown
SMBC Venture Capital Series Unknown
Mizuho Capital Series Unknown

Employee Profiles

Number of Employee Profiles
10
StemRIM has 10 current employee profiles, including Board member Yoji Kuwatari
Board member
Board member
Board member
Board member
Executive